IP Library › Granted Patent US 12,679,849
Granted Patent B2
US 12,679,849 · App. 17/598,524 · Granted Jul 14, 2026

Macrocyclic compounds as STING agonists

Inventors: Navnath Popat Karche (Taluka Mulshi, IN); Moloy Banerjee (Taluka Mulshi, IN); Pradeep Rangrao Patil (Taluka Mulshi, IN); Vinod Popatrao Vyavahare (Taluka Mulshi, IN); Deepak Sahebrao Walke (Taluka Mulshi, IN); Vaibhav Madhukar Kalhapure (Taluka Mulshi, IN); Vidya Ramdas (Taluka Mulshi, IN); Venkata P. Palle (Taluka Mulshi, IN); Rajender Kumar Kamboj (Taluka Mulshi, IN)
Assignee: LUPIN LIMITED
C07D498/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,679,849
App. No.
17/598,524
Filed
Sep 27, 2021
Granted
Jul 14, 2026
Kind
B2
Art Unit
1621
USPC
514/387
Abstract

Disclosed are the macrocyclic compounds having the general Formula (I) and their tautomeric forms, stereoisomers, pharmaceutically acceptable salts, and their combination with suitable medicament, corresponding processes for the synthesis and pharmaceutical compositions and uses of compounds disclosed herein.

Claims (72)

1 . A compound of Formula (Ia), its stereoisomer, or its pharmaceutically acceptable salt,

wherein,

R 2 is independently selected from hydrogen, optionally substituted C 1 -C 6 alkyl, and optionally substituted C 3 -C 5 monocyclic cycloalkyl;

ring A is independently selected from optionally substituted heterocyclyl, and optionally substituted heteroaryl;

m is selected from 0, or 1;

n is selected from 0, 1, or 2;

when ‘alkyl’ is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, alkyl, perhaloalkyl, cycloalkyl, heterocyclyl, —N(R 4 ) 2 , and —OR 4 ;

when ‘carbocycle’ or ‘cycloalkyl’ is substituted, it is substituted with 1 to 4 substituents independently selected from halogen, alkyl, perhaloalkyl, —N(R 4 ) 2 , and —OR 4 ;

when ‘heterocycle’ or ‘heterocyclyl’ is substituted, it is substituted with 1 to 4 substituents independently selected from oxo (═O), halogen, cyano, alkyl, perhaloalkyl, —OR 4 , —C(═O)OH, —OP(O)(OR 4 ) 2 , —P(O)(OR 4 ) 2 , —P(O)(OR 4 )R 4a , —SO 2 R 4a , —SO 2 NH 2 , —C(═O)N(H)R 4 , —C(═O)N(alkyl)R 4 , —N(H)C(═O)R 4a , —N(H)R 4 , and —N(alkyl)R 4 ;

when the ‘heteroaryl’ group is substituted, it is substituted with 1 to 4 substituents selected from halogen, cyano, alkyl, perhaloalkyl, —O-alkyl, —O-perhaloalkyl, —N(alkyl)alkyl, —N(H)R 4 , —SO 2 -alkyl, —N(alkyl)C(═O)alkyl, —N(H)C(═O)alkyl, —C(═O)N(alkyl)alkyl, —C(═O)N(H)alkyl, —C(═O)NH 2 , —SO 2 N(alkyl)alkyl, —SO 2 N(H)alkyl, —SO 2 NH 2 , —C(═O)OH, —OP(O)(OR 4 ) 2 , —P(O)(OR 4 ) 2 , and —P(O)(OR 4 )R 4a ;

each R 4 is independently selected from hydrogen, alkyl, and cycloalkyl; and

each R 4a is independently selected from alkyl, and cycloalkyl.

2 . The compound of Formula (Ia), its stereoisomer, or its pharmaceutically acceptable salt, as claimed in claim 1 , wherein, ring A is optionally substituted heterocyclyl or optionally substituted heteroaryl.

3 . The compound of Formula (Ia), its stereoisomer, or its pharmaceutically acceptable salt, as claimed in claim 1 , wherein, ring A is

4 . The compound of Formula (Ia), its stereoisomer, or its pharmaceutically acceptable salt, as claimed in claim 1 , wherein, R 2 is ethyl.

5 . The compound of Formula (Ia), its stereoisomer, or its pharmaceutically acceptable salt, as claimed in claim 1 , wherein, n is 0.

6 . The compound of Formula (Ia), its stereoisomer, or its pharmaceutically acceptable salt, as claimed in claim 1 , wherein, R 2 is C 1 -C 6 alkyl; n is 0, 1, or 2; and ring A is optionally substituted heterocyclyl or optionally substituted heteroaryl.

7 . The compound of Formula (Ia), its stereoisomer, or its pharmaceutically acceptable salt, as claimed in claim 1 , wherein, the compound is selected from:

(E)-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 1);

(E)-8-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 2);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-morpholino-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 3);

(E)-8-(4,4-difluoropiperidin-1-yl)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 4);

(E)-8-((2S,6R)-2,6-dimethylmorpholino)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 5);

(S,E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(3-methoxypyrrolidin-1-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 6);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(piperidin-1-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 7);

(E)-8-(azetidin-1-yl)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 8);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(1-methylpiperidin-4-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 9);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(piperazin-1-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 10);

(S,E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(3-hydroxypyrrolidin-1-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 11);

(R,E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(3-hydroxypyrrolidin-1-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 12);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(2-morpholinoethyl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 13);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-((1-methylazetidin-3-yl)methyl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 14);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-((1-methylpiperidin-4-yl)methyl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 15);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(morpholinomethyl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 16);

(E)-15-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(1-(2-fluoroethyl)-3-methyl-1H-pyrazole-5-carboxamido)-8-morpholino-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 17);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-((4-methylpiperazin-1-yl)methyl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 18);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(1H-imidazol-1-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 19);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(4-hydroxypiperidin-1-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 22);

(E)-8-(4-aminopiperidin-1-yl)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 23);

(S,E)-1-(4,12-dicarbamoyl-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diinden-8-yl) pyrrolidin-3-yl dihydrogen phosphate (Compound 24);

(E)-1-(4,12-dicarbamoyl-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diinden-8-yl) piperidin-4-yl dihydrogen phosphate (Compound 25);

(E)-8-(3-cyanopyrrolidin-1-yl)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 26);

(E)-8-(3-aminopyrrolidin-1-yl)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 27);

(R,E)-1-(4,12-dicarbamoyl-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diinden-8-yl) pyrrolidin-3-yl dihydrogen phosphate (Compound 28);

(E)-8-(4-cyanopiperidin-1-yl)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 29);

(E)-8-(azetidin-3-yl)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 30);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(piperidin-4-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 31);

(E)-1-(4,12-dicarbamoyl-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diinden-8-yl) pyrrolidine-3-carboxylic acid (Compound 32);

(E)-1-(4,12-dicarbamoyl-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diinden-8-yl) piperidine-4-carboxylic acid (Compound 33);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(1-methylazetidin-3-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 34);

(R,E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(3-methoxypyrrolidin-1-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 35); and

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(pyridin-2-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamidexamide (Compound 36).

8 . The compound of Formula (Ia), its stereoisomer, or its pharmaceutically acceptable salt, as claimed in claim 1 , wherein, the compound is selected from:

(E)-8-(8-oxa-3-azabicyclo[3.2.1]octan-3-yl)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 1);

(E)-8-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 2);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-morpholino-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 3);

(E)-8-(4,4-difluoropiperidin-1-yl)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 4);

(E)-8-((2S,6R)-2,6-dimethylmorpholino)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 5);

(S,E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(3-methoxypyrrolidin-1-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 6);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(1-methylpiperidin-4-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4, 12-dicarboxamide (Compound 9);

(S,E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(3-hydroxypyrrolidin-1-yl)-8,9,16,19-tetrahydro-7H-6, 10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 11);

(R,E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(3-hydroxypyrrolidin-1-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 12);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(2-morpholinoethyl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 13);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(morpholinomethyl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 16);

(E)-15-(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-1-(1-(2-fluoroethyl)-3-methyl-1H-pyrazole-5-carboxamido)-8-morpholino-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 17);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(1H-imidazol-1-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 19);

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(4-hydroxypiperidin-1-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 22);

(E)-8-(3-cyanopyrrolidin-1-yl)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 26);

(R,E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(3-methoxypyrrolidin-1-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamide (Compound 35); and

(E)-1,15-bis(1-ethyl-3-methyl-1H-pyrazole-5-carboxamido)-8-(pyridin-2-yl)-8,9,16,19-tetrahydro-7H-6,10-dioxa-2,14,15a, 19a-tetraazacyclopentadeca[3,2,1-cd:8,9,10-c′d′]diindene-4,12-dicarboxamidexamide (Compound 36).

9 . A pharmaceutical composition comprising the compound of Formula (Ia), or its pharmaceutically acceptable salt as claimed in claim 1 and at least one or more pharmaceutically acceptable excipient.

10 . A composition comprising a compound of Formula (Ia), or its pharmaceutically acceptable salt as claimed in claim 1 and an antigen or antigen composition.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 058568 FRAME: 0322. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Feb 1, 2022
From: KARCHE, NAVANTH POPAT; BANERJEE, MOLOY; PATIL, PRADEEP RANGRAO; VYAVAHARE, VINOD POPATRAO; WALKE, DEEPAK SAHEBRAO; KALHAPURE, VAIBHAV MADHUKAR; RAMDAS, VIDYA; PALLE, VENKATA P.; KAMBOJ, RAJENDER KUMAR
To: LUPIN LIMITED
Reel/Frame 058920/0382 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2021
From: KARCHE, NAVANTH POPAT; BANERJEE, MOLOY; PATIL, PRADEEP RANGRAO; VYAVAHARE, VINOD POPATRAO; WALKE, DEEPAK SAHEBRAO; KALHAPURE, VAIBHAV MADHUKAR; RAMDAS, VIDYA; PALLE, VENKATA P.; KAMBOJ, RAJENDER KUMAR
To: LUPIN LIMMITED
Reel/Frame 058568/0322 →
Priority Claims (2)
IN 201921012258 · Mar 28, 2019 · national
IN 201921046194 · Nov 13, 2019 · national
Continuity (1)
Related Publication 20220144852A1 · May 12, 2022
References Cited (25)
US 10981901B1 · Romano · 2021 [cited by examiner]
WO 2017011920A1 · 2017 [cited by applicant]
WO 2017175156A1 · 2017 [cited by applicant]
WO WO2017175147A1 · 2017 [cited by examiner]
WO 2018234808A1 · 2017 [cited by applicant]
WO 2018234805A1 · 2018 [cited by applicant]
WO 2018234807A1 · 2018 [cited by applicant]
WO 2019023635A1 · 2019 [cited by applicant]
WO 2019027857A1 · 2019 [cited by applicant]
WO 2019027858A1 · 2019 [cited by applicant]
PCT International Search Report and Written Opinion for PCT Application No. PCT/IB2020/052654 mailed May 26, 2020 (10 pages). [cited by applicant]
Barber, “Sting: Infection, Inflammation and Cancer,” Nature, 2015, 15:760-770. [cited by applicant]
Conlon et al., “Mouse, but not Human STING, Binds and Signals in Response to the Vascular Disrupting Agent 5,6-Dimethylxanthenone-4-Acetic Acid,” The Journal of Immunology, 2013, 190:5216-5225. [cited by applicant]
Corrales et al., “Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity,” Cell Reports, 2015, 11:1018-1030. [cited by applicant]
Deng et al., “STING-Dependent Cystolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors,” Immunity, 2014, 41:843-853. [cited by applicant]
Diamond et al., “Type I Interferon is Selectively Required by Dendritic Cells for Immune Rejection of Tumors,” J. Exp. Med., 2011, 208(10):1989-2003. [cited by applicant]
Galon et al., “Cancere Classification Using the Immunoscore: A Worldwide Task Force,” Journal of Translational Medicine, 2012, 10:205 (10 pages). [cited by applicant]
Guo et al., “STING Agonists Induce an Innate Antiviral Immune Response Against Hepatitis B Virus,” Antimicrobial Agents and Chemotherapy, 2015, 59(2):1273-1281. [cited by applicant]
Harlin et al., “Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell Recruitment,” Cancer Res., 2009, 69(7):3077-3085. [cited by applicant]
Ishikawa et al., “STING an Endoplasmic Recticulum Adaptor that Facilitates Innate Immune Signaling,” Nature, 2008, 455(7213):674-678. [cited by applicant]
Postow et al., “Targeting Immune Checkpoints: Releasing the Restraints on Anti-Tumor Immunity for Patients with Melanoma,” Cancer J., 2012, 18(2):153-159. [cited by applicant]
Ramanjulu et al., “Design of Amidobenzimidazole STING Receptor Agonists with Systemic Activity,” Nature, 2018, 564:439-443. [cited by applicant]
Sali et al., “Characterization of a Novel Human-Specific STING Agonist that Elicits Antiviral Activity Against Emerging Alphaviruses,” PLOS Pathogens, 2015 (30 pages). [cited by applicant]
Shirey et al., “The Anti-Tumor Agent, 5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA), Induces IFN-B-Mediated Antiviral Activity in vitro and in vivo,” Journal of Leukocyte Biology, 2011, 89:351-357. [cited by applicant]
Woo et al., “STING-Dependent Cytosolic DNA Sensing Mediaes Innate Immune Recognition of Immunogenic Tumors,” Immunity, 2014, 41:830-842. [cited by applicant]